<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03639870</url>
  </required_header>
  <id_info>
    <org_study_id>INFI-106-G2W3 (GC-011)</org_study_id>
    <nct_id>NCT03639870</nct_id>
  </id_info>
  <brief_title>Investigation of the Glaukos速 Trabecular Micro-Bypass System, Model iS3, in Subjects With Refractory Glaucoma</brief_title>
  <official_title>A Prospective, Multicenter Clinical Investigation of the Glaukos速 Trabecular Micro-Bypass System, Model iS3, in Subjects With Refractory Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaukos Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glaukos Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multi-center, single-arm clinical trial to evaluate the safety and effectiveness
      of the Glaukos速 Trabecular Micro-Bypass System Model iS3 (three stents per study eye) in
      subjects with refractory glaucoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, single arm, open-label clinical trial of the iS3 system.
      Up to 65 qualified subjects will be implanted with three G2-W stents in one eye and will be
      followed for 12 months postoperatively.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The iStent infinite Trabecular Micro-Bypass System Model iS3 is a sterile, single-use injector system that is pre-loaded with three G2-W stents, and is designed to deliver the stents into Schlemm's canal. The three G2-W stents are heparin-coated and manufactured from implant grade titanium.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary effectiveness endpoint</measure>
    <time_frame>Month 12 postoperative</time_frame>
    <description>The change in mean diurnal IOP from baseline at 12 months</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Implant Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Qualified eyes with refractory glaucoma will be implanted unilaterally with the Glaukos速 Trabecular Micro-Bypass System Model iS3 (three G2-W stents per study eye), and will be followed through 12 months postoperative.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Model iS3 three-stent trabecular micro-bypass system</intervention_name>
    <description>Provided in Arm/Group descriptions.</description>
    <arm_group_label>Implant Group</arm_group_label>
    <other_name>Implant Group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of refractory open-angle glaucoma (including pigmentary and
             pseudoexfoliative glaucoma) that is uncontrolled despite medical therapy and/or prior
             conventional incisional intraocular glaucoma surgeries.

          -  Phakic or pseudophakic.

          -  Males or females, 45 years of age or older.

        Exclusion Criteria:

          -  Traumatic, uveitic, neovascular, or angle-closure; or glaucoma associated with
             vascular disorders.

          -  Active corneal inflammation or edema.

          -  Retinal disorders not associated with glaucoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerry Stephens, O.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Glaukos Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Abhi Vilupuru, PhD BS (OD)</last_name>
    <phone>9493679600</phone>
    <email>avilupuru@glaukos.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Glaucoma Associates of Tx</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Davinder Grover, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <last_update_submitted>March 6, 2019</last_update_submitted>
  <last_update_submitted_qc>March 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

